RNA-based
Lilly and Haya Therapeutics Collaborate in $1 Billion Deal to Explore ‘Dark Genome’ for Obesity Treatments
Lilly, Haya Therapeutics, obesity, dark genome, RNA-based drug targets, biotech deal
Actionable Insights Powered by AI
Lilly, Haya Therapeutics, obesity, dark genome, RNA-based drug targets, biotech deal